FRM
RPTX

Fox Run Management’s Repare Therapeutics RPTX Stock Holding History

Fox Run Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,801
Closed -$143K – 850
2022
Q3 		$143K Buy
+11,801
New +$152K 0.06% 524

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fox Run Management's RPTX Position: Q4 2022 in Review

Fox Run Management sold out of Repare Therapeutics (RPTX) in Q4 2022, closing a stake of 11,801 shares — an estimated $143K sold.

Fox Run Management first reported a position in RPTX in Q3 2022 and held it in 1 quarter. The position peaked at $143K in Q3 2022. 82 funds tracked by Wall St. Rank hold RPTX as of Q4 2022.

  • Fox Run Management reported no remaining Repare Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Fox Run Management sold 11,801 Repare Therapeutics shares in Q4 2022, an estimated $143K.
  • Fox Run Management first reported a position in Repare Therapeutics in Q3 2022 and held it in 1 quarter.
  • Fox Run Management's Repare Therapeutics position peaked at $143K in Q3 2022.
  • 82 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2022.

Based on Fox Run Management's 13F filing for Q4 2022, filed 7 Feb 2023.